Nuvation Bio NUVB Research And Development Service Revenue — Milestone Received

Similar metrics at other companies

ZYMEMilestone revenue — Research and development collaborations

$0-100%

ZYMEResearch Milestone — Research and development collaborations (note 11)

$8.75M—

ZYMEResearch, Development and Commercial Milestones — Research and development collaborations (note 11)

$0—

BBIOResearch and Development Services — Contract with customer, liability

$2.7M—

IONSResearch And Development Revenue — Revenue

$138.28M+149%

INVAResearch And Development Support — Future Potential Milestone Payment

$91M0.0%

Other financials

Income statement

See full

Revenue$83.2M+2,599%

Gross profit$9.8M+1,340%

Operating income$3.9M+107%

Net income$5.4M+110%

EPS (diluted)$0.01+106%

Balance sheet

See full

Cash & equivalents$125.4M+161%

Total debt$57.2M+401%

Total equity$319.6M-23.8%

Total assets$610.2M+23.9%

Cash flow

See full

Operating cash flow$5.1M+112%

CapEx$48.0K-33.3%

Free cash flow$5.0M+112%

Valuation

See full

Market cap$2.25B+150%

Profitability

See full

Gross margin54.3%+39.5pp

Operating margin-105%-52.0pp

Net margin-102.1%-50.6pp

FCF margin-93.5%-45.2pp

Returns & leverage

See full

Return on equity-39.5%-15.8pp

Debt / equity0.2×+0.2×

Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept nuvb:MilestoneReceived.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's research and development service revenue — milestone received.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nuvation Bio's research and development service revenue — milestone received?: Nuvation Bio (NUVB) reported research and development service revenue — milestone received of $3.8M in Q4 2025.
What does research and development service revenue — milestone received mean?: This represents cash or contractual payments received upon the successful achievement of predefined research, development, or regulatory milestones. These payments are typically non-recurring and contingent upon the progress of therapeutic candidates. Tracking these receipts is essential for evaluating the company's ability to hit critical clinical development targets and generate non-dilutive funding.